Increased Severity of Ulcerative Colitis in the Terminal Phase of the Metabolic Syndrome

Ulcerative colitis is chronic immune-mediated disorder that affects primarily colonic mucosa. The metabolic syndrome has increasing global prevalence with a significant impact on biology of chronic diseases, such as ulcerative colitis. Today it is known that the metabolic syndrome attenuates severit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Tohoku journal of experimental medicine Ročník 254; číslo 3; s. 171
Hlavní autoři: Jovanovic, Marina Milun, Jurisevic, Milena Milenko, Gajovic, Nevena Miroslav, Arsenijevic, Nebojsa Nikola, Jocic, Miodrag Vukasin, Jovanovic, Ivan Petar, Zdravkovic, Natasa Dragan, Djukic, Aleksandar Ljubodrag, Maric, Veljko Jovo, Jovanovic, Milan Milorad
Médium: Journal Article
Jazyk:angličtina
Vydáno: Japan 2021
Témata:
ISSN:1349-3329, 1349-3329
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Ulcerative colitis is chronic immune-mediated disorder that affects primarily colonic mucosa. The metabolic syndrome has increasing global prevalence with a significant impact on biology of chronic diseases, such as ulcerative colitis. Today it is known that the metabolic syndrome attenuates severity of ulcerative colitis. Still, there is no evidence that different stages of metabolic syndrome alter the course of the ulcerative colitis. The aim of this study was to dissect out how progression of the metabolic syndrome impacted the biology of ulcerative colitis and severity of clinical presentation. Seventy-two patients (41 men and 31 women, 22-81 years old) were enrolled in this observational cross-sectional study. Concentrations of pro- and anti-inflammatory cytokines in serum and feces samples were measured and phenotype of colon infiltrating cells was analyzed. Patients in the terminal phase of the metabolic syndrome have clinically and pathohistologically more severe form of ulcerative colitis, which is followed by decreased concentrations of systemic galectin-1, increased values of systemic pro-inflammatory mediators and increased influx of lymphocytes in affected colon tissue. Our data suggest that reduced concentrations of galectin-1 and predomination of the pro-inflammatory mediators in patients with terminal stage of the metabolic syndrome enhance local chronic inflammatory response and subsequent tissue damage, and together point on important role of galectin-1 in immune response in ulcerative colitis patients with the metabolic syndrome.
AbstractList Ulcerative colitis is chronic immune-mediated disorder that affects primarily colonic mucosa. The metabolic syndrome has increasing global prevalence with a significant impact on biology of chronic diseases, such as ulcerative colitis. Today it is known that the metabolic syndrome attenuates severity of ulcerative colitis. Still, there is no evidence that different stages of metabolic syndrome alter the course of the ulcerative colitis. The aim of this study was to dissect out how progression of the metabolic syndrome impacted the biology of ulcerative colitis and severity of clinical presentation. Seventy-two patients (41 men and 31 women, 22-81 years old) were enrolled in this observational cross-sectional study. Concentrations of pro- and anti-inflammatory cytokines in serum and feces samples were measured and phenotype of colon infiltrating cells was analyzed. Patients in the terminal phase of the metabolic syndrome have clinically and pathohistologically more severe form of ulcerative colitis, which is followed by decreased concentrations of systemic galectin-1, increased values of systemic pro-inflammatory mediators and increased influx of lymphocytes in affected colon tissue. Our data suggest that reduced concentrations of galectin-1 and predomination of the pro-inflammatory mediators in patients with terminal stage of the metabolic syndrome enhance local chronic inflammatory response and subsequent tissue damage, and together point on important role of galectin-1 in immune response in ulcerative colitis patients with the metabolic syndrome.
Ulcerative colitis is chronic immune-mediated disorder that affects primarily colonic mucosa. The metabolic syndrome has increasing global prevalence with a significant impact on biology of chronic diseases, such as ulcerative colitis. Today it is known that the metabolic syndrome attenuates severity of ulcerative colitis. Still, there is no evidence that different stages of metabolic syndrome alter the course of the ulcerative colitis. The aim of this study was to dissect out how progression of the metabolic syndrome impacted the biology of ulcerative colitis and severity of clinical presentation. Seventy-two patients (41 men and 31 women, 22-81 years old) were enrolled in this observational cross-sectional study. Concentrations of pro- and anti-inflammatory cytokines in serum and feces samples were measured and phenotype of colon infiltrating cells was analyzed. Patients in the terminal phase of the metabolic syndrome have clinically and pathohistologically more severe form of ulcerative colitis, which is followed by decreased concentrations of systemic galectin-1, increased values of systemic pro-inflammatory mediators and increased influx of lymphocytes in affected colon tissue. Our data suggest that reduced concentrations of galectin-1 and predomination of the pro-inflammatory mediators in patients with terminal stage of the metabolic syndrome enhance local chronic inflammatory response and subsequent tissue damage, and together point on important role of galectin-1 in immune response in ulcerative colitis patients with the metabolic syndrome.Ulcerative colitis is chronic immune-mediated disorder that affects primarily colonic mucosa. The metabolic syndrome has increasing global prevalence with a significant impact on biology of chronic diseases, such as ulcerative colitis. Today it is known that the metabolic syndrome attenuates severity of ulcerative colitis. Still, there is no evidence that different stages of metabolic syndrome alter the course of the ulcerative colitis. The aim of this study was to dissect out how progression of the metabolic syndrome impacted the biology of ulcerative colitis and severity of clinical presentation. Seventy-two patients (41 men and 31 women, 22-81 years old) were enrolled in this observational cross-sectional study. Concentrations of pro- and anti-inflammatory cytokines in serum and feces samples were measured and phenotype of colon infiltrating cells was analyzed. Patients in the terminal phase of the metabolic syndrome have clinically and pathohistologically more severe form of ulcerative colitis, which is followed by decreased concentrations of systemic galectin-1, increased values of systemic pro-inflammatory mediators and increased influx of lymphocytes in affected colon tissue. Our data suggest that reduced concentrations of galectin-1 and predomination of the pro-inflammatory mediators in patients with terminal stage of the metabolic syndrome enhance local chronic inflammatory response and subsequent tissue damage, and together point on important role of galectin-1 in immune response in ulcerative colitis patients with the metabolic syndrome.
Author Jovanovic, Marina Milun
Maric, Veljko Jovo
Zdravkovic, Natasa Dragan
Gajovic, Nevena Miroslav
Arsenijevic, Nebojsa Nikola
Djukic, Aleksandar Ljubodrag
Jurisevic, Milena Milenko
Jocic, Miodrag Vukasin
Jovanovic, Ivan Petar
Jovanovic, Milan Milorad
Author_xml – sequence: 1
  givenname: Marina Milun
  surname: Jovanovic
  fullname: Jovanovic, Marina Milun
  organization: Department of Internal medicine, Faculty of Medical Sciences, University of Kragujevac
– sequence: 2
  givenname: Milena Milenko
  surname: Jurisevic
  fullname: Jurisevic, Milena Milenko
  organization: Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac
– sequence: 3
  givenname: Nevena Miroslav
  surname: Gajovic
  fullname: Gajovic, Nevena Miroslav
  organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac
– sequence: 4
  givenname: Nebojsa Nikola
  surname: Arsenijevic
  fullname: Arsenijevic, Nebojsa Nikola
  organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac
– sequence: 5
  givenname: Miodrag Vukasin
  surname: Jocic
  fullname: Jocic, Miodrag Vukasin
  organization: Institute for Transfusiology and Haemobiology, Military Medical Academy
– sequence: 6
  givenname: Ivan Petar
  surname: Jovanovic
  fullname: Jovanovic, Ivan Petar
  organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac
– sequence: 7
  givenname: Natasa Dragan
  surname: Zdravkovic
  fullname: Zdravkovic, Natasa Dragan
  organization: Department of Internal medicine, Faculty of Medical Sciences, University of Kragujevac
– sequence: 8
  givenname: Aleksandar Ljubodrag
  surname: Djukic
  fullname: Djukic, Aleksandar Ljubodrag
  organization: Department of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac
– sequence: 9
  givenname: Veljko Jovo
  surname: Maric
  fullname: Maric, Veljko Jovo
  organization: Department of Surgery, Faculty of Medicine Foca, University of East Sarajevo
– sequence: 10
  givenname: Milan Milorad
  surname: Jovanovic
  fullname: Jovanovic, Milan Milorad
  organization: Department of Abdominal surgery, Military Medical Academy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34248084$$D View this record in MEDLINE/PubMed
BookMark eNpNkM1Lw0AQxRep2A-9eZY9ekndr-wmRylWCxWFtuAtTJIJ3ZKPurst9L83xQqeZhh-b3jvjcmg7Vok5J6zKdeCPYUdNlMRqyk3_IqMuFRpJKVIB__2IRl7v2NMKmb0DRlKJVTCEjUiX4u2cAgeS7rCIzobTrSr6KYu0EGwR6SzrrbBempbGrZI1-ga20JNP7e96syer-8YIO_Bgq5Obem6Bm_JdQW1x7vLnJDN_GU9e4uWH6-L2fMyKmJjQoSiwgohByUZB0ygKjiTmApApnWq44rFWsi8MCZOcgFGmN66RgBRGlQgJuTx9-_edd8H9CFrrC-wrqHF7uAzEcdM97nTpEcfLughb7DM9s424E7ZXxviB4akY1I
CitedBy_id crossref_primary_10_3390_metabo12100930
crossref_primary_10_3748_wjg_v31_i25_107260
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1620/tjem.254.171
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1349-3329
ExternalDocumentID 34248084
Genre Journal Article
Observational Study
GroupedDBID ---
-~X
.55
.GJ
123
29Q
2WC
36B
3O-
53G
5RE
7.U
ABCQX
ACGFO
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
ECM
EIF
EMB
EMOBN
F5P
GX1
JSF
JSH
KQ8
L7B
MK0
M~E
NPM
OK1
P2P
RJT
RNS
RZJ
SV3
TKC
TR2
W2D
WH7
X7J
X7M
XSB
ZGI
ZXP
7X8
OVT
ID FETCH-LOGICAL-c577t-e2fefeaba4301ae8afc103e92ae066965f05623bc7758b2a7272486eaa2d7e4a2
IEDL.DBID 7X8
ISICitedReferencesCount 4
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000693259900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1349-3329
IngestDate Wed Oct 01 13:57:46 EDT 2025
Thu Jan 02 22:56:43 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords ulcerative colitis
immune response
disease severity
metabolic syndrome progression
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c577t-e2fefeaba4301ae8afc103e92ae066965f05623bc7758b2a7272486eaa2d7e4a2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.jstage.jst.go.jp/article/tjem/254/3/254_171/_pdf
PMID 34248084
PQID 2550634098
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2550634098
pubmed_primary_34248084
PublicationCentury 2000
PublicationDate 2021-00-00
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – year: 2021
  text: 2021-00-00
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle Tohoku journal of experimental medicine
PublicationTitleAlternate Tohoku J Exp Med
PublicationYear 2021
SSID ssj0034076
Score 2.2648485
Snippet Ulcerative colitis is chronic immune-mediated disorder that affects primarily colonic mucosa. The metabolic syndrome has increasing global prevalence with a...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 171
SubjectTerms Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents - therapeutic use
Colitis, Ulcerative - drug therapy
Colon
Female
Humans
Intestinal Mucosa
Male
Metabolic Syndrome - complications
Middle Aged
Young Adult
Title Increased Severity of Ulcerative Colitis in the Terminal Phase of the Metabolic Syndrome
URI https://www.ncbi.nlm.nih.gov/pubmed/34248084
https://www.proquest.com/docview/2550634098
Volume 254
WOSCitedRecordID wos000693259900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEbym3d2k-ziJFIuXlkJb2FvJY4KVultt9fc72U31JAhe9pBN2GX4Mvkm8zFDyF1sNMLWSBbyMGZC8oClqTJONI6nrdJBaGzVbCIZDNI8z4b-wm3pZZVrn1g5alNqd0feRuqLpylGI-n94o25rlEuu-pbaGySBkcq41Cd5N9ZBJxdNZdzFfgY51Hmhe9xFLRXL_DawuCoFSbh7-SyOmR6-__9vQOy5-klfajxcEg2oDgiO32fQD8mOfoDJ0MHQ0eAKEYOTktLJ3MNdQlw2q0EcUs6KyhyQzquxTJzOnzGVW6uG-3DCsEzn2k68hUPTsik9zjuPjHfXIHpTpKsGEQWLEglBW5xCam0Ogw4ZJEEZCFZ3LEVNVI6wYhCRdIlbEUag5SRSUDI6JRsFWUB54Rqhe8sx8BIKNFRRrkCPtxqC5mxiosmuV3bbIrgdRkJWUD5sZz-WK1JzmrDTxd1lY0pF_i9IBUXf1h9SXYjpzWprkauSMPi1oVrsq0_0WDvNxUq8DkY9r8AwvXCfg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+Severity+of+Ulcerative+Colitis+in+the+Terminal+Phase+of+the+Metabolic+Syndrome&rft.jtitle=Tohoku+journal+of+experimental+medicine&rft.au=Jovanovic%2C+Marina+Milun&rft.au=Jurisevic%2C+Milena+Milenko&rft.au=Gajovic%2C+Nevena+Miroslav&rft.au=Arsenijevic%2C+Nebojsa+Nikola&rft.date=2021-01-01&rft.eissn=1349-3329&rft.volume=254&rft.issue=3&rft.spage=171&rft_id=info:doi/10.1620%2Ftjem.254.171&rft_id=info%3Apmid%2F34248084&rft_id=info%3Apmid%2F34248084&rft.externalDocID=34248084
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1349-3329&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1349-3329&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1349-3329&client=summon